2003 Volume 50 Issue 3 Pages 355-359
The purpose of the present study was to investigate changes in serum leptin levels during GnRH agonist therapy. Twenty regularly menstruating women with uterine leiomyomas were enrolled. These subjects were given GnRH agonist (leuprorelin acetate, 3.75 mg) monthly for 4 months. Serum leptin and estradiol (E2) levels were measured at the two time points of day 1 or 2 of the menstrual cycle and the end of GnRH agonist therapy. Weight, total body fat mass, percentage of body fat, and total body lean mass were measured by whole body scanning with dual-energy X-ray absorptiometry. The ratio of serum leptin levels to total body fat mass (leptin-fat mass ratio), and the ratio of serum leptin levels to total body lean mass (leptin-lean mass ratio) were calculated. All subjects became amenorrheic after the initial administration of GnRH agonist. Baseline E2 levels were 45.4 ± 21.0 pg/mL, which significantly decreased after GnRH agonist therapy (13.3 ± 4.2 pg/mL, p<0.01). Baseline leptin levels were 8.7 ± 8.1 ng/mL, which did not differ from the values after 4 months of GnRH agonist administration (8.9 ± 6.8 ng/mL). Total body fat mass significantly increased from 20.0 ± 10.4 to 21.0 ± 9.4 kg (p<0.05), while total body lean mass significantly decreased (34.5 ± 4.2 kg to 33.3 ± 3.9 kg, p<0.01). However, leptin-fat mass ratio after GnRH agonist therapy did not differ from the baseline values (0.39 ± 0.16 ng/mL/kg vs 0.38 ± 0.16 ng/mL/kg). Hypogonadism does not have a major impact on circulating leptin levels.
